Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Inclusion Criteria: * Metastatic castration-resistant prostate cancer (mCRPC), with progressive disease per PCWG3 criteria during or following the direct prior line of therapy. * Measurable disease per RECIST v1.1 at baseline; subjects with mCRPC with bone only metastases must have measurable PSA. * Age ≥18 years. * Life expectancy \> 12 weeks. * ECOG 0-1 * Adequate organ function. Exclusion Criteria: * Prostate cancer with unstable bone lesions or symptomatic/untreated coagulopathy, or history of \> Grade 2 hematuria within the previous 6 months. * Prior CAR T cell or other genetically-modified T cell therapy. Prior treatment with an immune-based therapy for the treatment of prostate cancer, including cancer vaccine therapies are allowable. * Symptomatic, untreated, or actively progressing central nervous system metastases. * Impaired cardiac function or clinically significant cardiac disease. * Pregnant or breastfeeding. * Participant requires chronic, systemic steroid therapy. * Severe intercurrent infection. * Known HIV positivity.